Literature DB >> 26902255

Multidrug Resistance Acinetobacter Bacteremia Secondary to Ventilator-Associated Pneumonia: Risk Factors and Outcome.

Evgeni Brotfain1, Abraham Borer2, Leonid Koyfman1, Lisa Saidel-Odes2, Amit Frenkel1, Shaun E Gruenbaum3, Vsevolod Rosenzweig1, Alexander Zlotnik1, Moti Klein1.   

Abstract

PURPOSE: Acinetobacter baumannii is a multidrug resistant (MDR), gram-negative bacterium commonly implicated in ventilator-associated pneumonia (VAP) in critically ill patients. Patients in the intensive care unit (ICU) with VAP often subsequently develop A baumannii bacteremia, which may significantly worsen outcomes.
MATERIALS AND METHODS: In this study, we retrospectively reviewed the clinical and laboratory records of 129 ICU patients spanning 6 years with MDR A baumannii VAP; 46 (35%) of these patients had concomitant MDR A baumannii bacteremia.
RESULTS: The ICU mortality rate was higher in patients with VAP having A baumannii bacteremia compared to nonbacteremic patients (32.4% vs 9.6% respectively, P < .005). Age >65 years, an Acute Physiology and Chronic Health Evaluation II (APACHE-II) score higher than 20, a Sequential Organ Failure Assessment (SOFA) score higher than 7 on the day of bacteremia, and the presence of comorbid disease (chronic obstructive pulmonary disease [COPD] and chronic renal failure) were found to be independent risk factors for in-hospital mortality in this population. Multidrug resistant A baumannii was not an independent risk factor for mortality.
CONCLUSION: Although the presence of comorbid diseases (COPD and chronic renal failure) and severity of disease (APACHE > 20 and SOFA >7) were found to be independent risk factors for ICU mortality, MDR A baumannii bacteremia was not an independent risk factor for mortality in our critically ill population.

Entities:  

Keywords:  Acinetobacter baumannii; multidrug resistant Acinetobacter VAP; multidrug resistant Acinetobacter bacteremia; outcome; risk factor

Mesh:

Year:  2016        PMID: 26902255     DOI: 10.1177/0885066616632193

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  10 in total

1.  Acinetobacter baumannii Outer Membrane Protein A Induces Pulmonary Epithelial Barrier Dysfunction and Bacterial Translocation Through The TLR2/IQGAP1 Axis.

Authors:  Wang Zhang; Hua Zhou; Yan Jiang; Jintao He; Yue Yao; Jianfeng Wang; Xiaochen Liu; Sebastian Leptihn; Xiaoting Hua; Yunsong Yu
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

2.  Treatment, Clinical Outcomes, and Predictors of Mortality among a National Cohort of Admitted Patients with Acinetobacter baumannii Infection.

Authors:  Haley J Appaneal; Vrishali V Lopes; Kerry L LaPlante; Aisling R Caffrey
Journal:  Antimicrob Agents Chemother       Date:  2022-01-10       Impact factor: 5.938

3.  Development and Validation of a Model for Predicting the Risk of Death in Patients with Acinetobacter baumannii Infection: A Retrospective Study.

Authors:  Hui Zhang; Yayun Zhao; Yahong Zheng; Qinxiang Kong; Na Lv; Yanyan Liu; Dongmei Zhao; Jiabin Li; Ying Ye
Journal:  Infect Drug Resist       Date:  2020-08-10       Impact factor: 4.003

4.  Determinants of Mortality in Patients with Nosocomial Acinetobacter baumannii Bacteremia in Southwest China: A Five-Year Case-Control Study.

Authors:  Shuangshuang Yang; Jide Sun; Xianan Wu; Liping Zhang
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-06-03       Impact factor: 2.471

5.  Origin of Sepsis Associated with the Short-Term Mortality of Patients: A Retrospective Study Using the eICU Collaborative Research Database.

Authors:  Qinglin Li; Yingmu Tong; Hai Wang; Jie Ren; Sinan Liu; Tong Liu; Kai Qu; Chang Liu; Jingyao Zhang
Journal:  Int J Gen Med       Date:  2021-12-24

Review 6.  Vaccine development to control the rising scourge of antibiotic-resistant Acinetobacter baumannii: a systematic review.

Authors:  Ravinder Singh; Neena Capalash; Prince Sharma
Journal:  3 Biotech       Date:  2022-03-02       Impact factor: 2.406

7.  Risk factors for mortality in ICU patients with Acinetobacter baumannii ventilator-associated pneumonia: impact of bacterial cytotoxicity.

Authors:  Mohan Ju; Dongni Hou; Shu Chen; Ying Wang; Xinjun Tang; Jie Liu; Cuicui Chen; Yuanlin Song; Huayin Li
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

8.  Multidrug-resistant Acinetobacter baumannii outbreaks: a global problem in healthcare settings.

Authors:  Mariana Neri Lucas Kurihara; Romário Oliveira de Sales; Késia Esther da Silva; Wirlaine Glauce Maciel; Simone Simionatto
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-06       Impact factor: 1.581

9.  Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia.

Authors:  Fang-Yu Kang; Chorng-Kuang How; Yung-Chih Wang; Aristine Cheng; Ya-Sung Yang; Shu-Chen Kuo; Chang-Pan Liu; Yuag-Meng Liu; Te-Li Chen; Yi-Tzu Lee
Journal:  Antimicrob Resist Infect Control       Date:  2020-09-29       Impact factor: 4.887

10.  Antimicrobial Random Peptide Mixtures Eradicate Acinetobacter baumannii Biofilms and Inhibit Mouse Models of Infection.

Authors:  Hannah E Caraway; Jonathan Z Lau; Bar Maron; Myung Whan Oh; Yael Belo; Aya Brill; Einav Malach; Nahed Ismail; Zvi Hayouka; Gee W Lau
Journal:  Antibiotics (Basel)       Date:  2022-03-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.